Loading
A phase 2 trial of Olaparib and Ceralasertib in triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. is a phase 2 interventional study registered as NCT03330847 by AstraZeneca, with 273 participants enrolled, started 2018-03-07 and due to reach its primary completion in 2020-11-13. Interventions recorded: Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). and Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
273 enrolled.
90% CI 2.9 to 5.4; Figures from the ClinicalTrials.gov results section (first posted 2022-03-22), not from a publication · 90% CI 3.7 to 5.5 · 90% CI 3.7 to 5.6
SourceFigures from the ClinicalTrials.gov results section (first posted 2022-03-22), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free Survival (Per BICR), All patients per BICR | Olaparib Monotherapy | 114 | 3.6 months | - | - | link |
| Olaparib + Ceralasertib | 112 | 5.3 months | ||||
| Olaparib + Adavosertib | 47 | 3.8 months | ||||
| Number of Patients With Objective Response (Per BICR and Per Sensitivity Analysis), All patients per BICR | Olaparib Monotherapy | 114 | 24 participants | - | - | link |
| Olaparib + Ceralasertib | 112 | 32 participants | ||||
| Olaparib + Adavosertib | 47 | 9 participants |
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares Ceralasertib, AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares Metastatic triple-negative breast cancer, AstraZeneca, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib and the tag pipeline.